Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.


TSXV:ARCH - Post by User

Post by Viking2233on Jul 02, 2023 9:31am
167 Views
Post# 35524137

Co-ordinated Short Attack

Co-ordinated Short AttackHappy Canada Day!

It is abundantly clear that there is a co-ordinated short attack being utilized against ARCH. It is frustrating that bonafide solid news released over the padt few months has had zero positive impact on moving the share price up.

The shorts (CIBC & Scotiabank) are aggressively selling to keep the share price below $2 when fair value should ge $10-15 with current news plus where we are in the scientific process.

I know we all want to blame the shorts but how can you when they see a lame duck with zero buying interest. This will continue to happen until we attract serious buying interest. The shorts drive the share price lower daily but zero buyers step in. Unfortunately until we have buyers coming in we are in limbo.

Take this opportunity to add if and when you can as this will not go on forever and this is a gift of a lifetime. Don't let the shorts steal your shares.
<< Previous
Bullboard Posts
Next >>